Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
Recruiting · NCT06130995 · Registry updated 2026-03-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Relugolix + Enzalutamide Study in High-Risk Prostate Cancer | Disease Attributes, Disease Progression, Neoplasm, Residual, Neoplastic Processes, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 1 | 2026-03-05 | NCT06130995 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Astellas Pharma Inc | 43 |
| Pfizer | 431 |
| University of Oklahoma | 146 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Stephenson Cancer Center at OU Health, University of Oklahoma Health Sciences Center (SCC-OUHSC) | Oklahoma City | United States | 1 |